Forte Biosciences, Inc. 8-K

What Happened

• On July 9, 2026, Forte Biosciences, Inc. (FBRX) announced positive results from its FB102 double-blind, placebo-controlled Phase 1b study in vitiligo and issued a press release to that effect. The company held a conference call the same day at 8:30 a.m. ET to review the study results. The press release and the FB102 Phase 1b vitiligo data presentation were furnished as exhibits to the Form 8-K.

Key Details

• Study: FB102, double-blind, placebo-controlled Phase 1b in vitiligo — reported as producing positive results (announced July 9, 2026).
• Conference call: Scheduled and held at 8:30 a.m. ET on July 9, 2026 to discuss the results.
• Filing items: Disclosure furnished under Item 7.01 (press release) and Item 8.01 (data presentation); materials attached as Exhibit 99.1 (press release) and Exhibit 99.2 (presentation).
• The data presentation is incorporated by reference in the 8-K and was reviewed on the call.

Why It Matters

• Positive Phase 1b results are an important clinical milestone for Forte’s FB102 program in vitiligo and can reduce early-stage development risk by demonstrating safety/initial efficacy signals (as reported).
• The announcement and accompanying presentation give investors direct access to the company’s clinical data and management commentary via the press release and conference call.
• There were no other material corporate actions (e.g., financings, executive changes) reported in this 8-K; the filing is focused on clinical progress and investor disclosure.